Merck (MRK) Restructuring Costs (2009 - 2026)
Merck (MRK) posted quarterly Restructuring Costs of $195.0 million for Q1 2026, up 182.61% year-over-year from $69.0 million in Q1 2025, and down 8.45% quarter-over-quarter from $213.0 million in Q4 2025.
Merck (MRK) Restructuring Costs (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Restructuring Costs for 18 consecutive years, with $195.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Restructuring Costs rose 182.61% year-over-year to $195.0 million; the TTM figure through Mar 2026 stood at $1.0 billion (up 296.48% YoY), while the FY2025 annual figure was $889.0 million, up 187.7% from the prior year.
- Restructuring Costs fell to $195.0 million in Q1 2026 per MRK's latest filing, from $213.0 million in the prior quarter.
- Across five years, Restructuring Costs topped out at $560.0 million in Q2 2025 and bottomed at $47.0 million in Q3 2025.
- Historically, Restructuring Costs has averaged $137.1 million across 5 years, with a median of $94.0 million in 2022.
- Annual changes were most pronounced in 2022 — Restructuring Costs slumped 82.15% — and 2025, when it jumped 600.0%.
- Merck's Restructuring Costs stood at $49.0 million in 2022, then soared by 420.41% to $255.0 million in 2023, then tumbled by 80.0% to $51.0 million in 2024, then surged by 317.65% to $213.0 million in 2025, then dropped by 8.45% to $195.0 million in 2026.
- Business Quant data shows MRK's Restructuring Costs at $195.0 million in Q1 2026, $213.0 million in Q4 2025, and $47.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 151.00 Mn |
| Mar 31, 2026 | 195.00 Mn |
| Dec 31, 2025 | 213.00 Mn |
| Sep 30, 2025 | 47.00 Mn |
| Jun 30, 2025 | 560.00 Mn |
| Mar 31, 2025 | 69.00 Mn |
| Dec 31, 2024 | 51.00 Mn |
| Sep 30, 2024 | 56.00 Mn |
| Jun 30, 2024 | 80.00 Mn |
| Mar 31, 2024 | 123.00 Mn |
| Dec 31, 2023 | 255.00 Mn |
| Sep 30, 2023 | 126.00 Mn |
| Jun 30, 2023 | 151.00 Mn |
| Mar 31, 2023 | 67.00 Mn |
| Dec 31, 2022 | 49.00 Mn |
| Sep 30, 2022 | 94.00 Mn |
| Jun 30, 2022 | 142.00 Mn |
| Mar 31, 2022 | 53.00 Mn |
| Dec 31, 2021 | 174.00 Mn |
| Sep 30, 2021 | 107.00 Mn |